











# Clinical Trials for Middle and High School

| Newly Diagnosed Clinical Trials   |  |   |
|---|--|---|
| <br>DRUG | <b><u>JAKPOT-T1D</u></b><br>AGES 12-35<br>T1D LESS THAN 100 DAYS, A1C <10%<br>LOCATION: MA   |  |
| <br>DRUG | <b><u>T1D RELAY</u></b><br>AGES 8-45<br>T1D LESS THAN 100 DAYS<br>LOCATION: MA               |  |
| <br>DRUG | <b><u>DIAGNODE-3</u></b><br>AGES 12-28<br>WITHIN 6 MONTHS OF DIAGNOSIS<br>LOCATION: MA       |  |
| <br>DRUG | <b><u>FABULINUS</u></b><br>AGES 12-35<br>T1D LESS THAN 90 DAYS W/ 1 ANTIBODY<br>LOCATION: MA |  |

# In Person Clinical Trials



OBSERVATIONAL

## **IMMUNE FUNCTION**

ALL AGES T1DS AND/OR  
FAMILY MEMBERS OF T1DS  
EARN \$20  
LOCAL LAB



DRUG

## **REPEAT BCG VACCINATIONS**

AGES 12-17  
T1D AT LEAST 2 YEARS  
LOCATION: MA



OBSERVATIONAL

## **BONE HEALTH IN T1D YOUTH**

AGES 6-20  
WITH T1D AND WITHOUT T1D  
EARN UP TO \$300  
LOCATION: MA



BEHAVIORAL

## **iACT FOR EATING DISORDERS**



AGES 16-45  
LIVING W/ EATING DISORDER  
LOCATION: RI



SURVEY

## **SPOTLIGHT AQ**

AGES 16 - 25  
BOSTON CHILDREN'S PATIENTS  
LOCATION: MA

















DEVICE







## **STRIVE STUDY**



AGES 2-70  
T1D AT LEAST 3 MONTHS (2-6) OR 1 YEAR (7-70)  
CURRENT OMNIPOD 5 USER  
LOCATION: MA



# Virtual Clinical Trials

|   |  |   |
|---|--|---|
| <br>SURVEY       | <b><u>TIDES</u></b><br>AGES 13-17<br>COMPENSATION<br>VIRTUAL   |    |
| <br>PREVENTION   | <b><u>TRIALNET</u></b><br>DIRECT RELATIVES OF<br>T1DS AGES 2-45<br>UNDER 18 CAN RESCREEN EVERY 2 YEARS<br>VIRTUAL OR TRIALNET CENTER |    |
| <br>DEVICE     | <b><u>EXTENDED BOLUS CLOSED LOOP</u></b><br>AGES 13-18<br>T1D AT LEAST 1 YEAR<br>USING CONTROL IQ<br>VIRTUAL                         |  |
| <br>BEHAVIORAL | <b><u>DIGITAL STORYTELLING FOR TEENS</u></b><br>AGES 13-21<br>T1D FOR AT LEAST 1 YEAR<br>VIRTUAL                                     |  |
| <br>SURVEY     | <b><u>DIABETES CARE IN SCHOOLS:<br/>A GLOBAL ONLINE SURVEY</u></b><br>CAREGIVERS OF SCHOOL<br>AGED T1DS<br>VIRTUAL                   |  |
| <br>BEHAVIORAL | <b><u>T1DAL</u></b><br>AGES 13-18 T1D AT LEAST 6 MONTHS<br>EARN UP TO \$125<br>VIRTUAL   |  |
| <br>BEHAVIORAL | <b><u>TRANSDISCIPLINARY CARE FOR<br/>TRANSITION</u></b><br>AGES 17-25 APPROACHING PEDIATRIC<br>DISCHARGE - EARN \$180<br>VIRTUAL     |  |

|  |  |  |
|--|--|--|
| <br><b>SURVEY</b>     | <b><u>T1D EXCHANGE REGISTRY</u></b><br><b>INDIVIDUALS WITH T1D AND/OR THEIR CAREGIVERS</b><br><br><b>VIRTUAL</b>   |   |
| <br><b>BEHAVIORAL</b> | <b><u>T1D BODY ACCEPTANCE PROJECT</u></b><br><b>FEMALES AGES 15-30 W/ BODY IMAGE CONCERNS AND/OR DISORGANIZED EATING EARN \$110</b><br><br><b>VIRTUAL/MA</b> |   |
| <br><b>SURVEY</b>    | <b><u>DIABETES TEEN WELLNESS</u></b><br><b>AGES 11-17 USING CGM EARN \$125</b><br><br><b>VIRTUAL</b>   |  |

| Early Stage T1D Trial   |   |   |
|---|---|---|
| <br><b>OBSERVATIONAL</b> | <b><u>PREDICT</u></b><br><b>AGES 12-30</b><br><b>AT LEAST 1 T1D ANTIBODY - EARN \$1500</b><br><br><b>LOCATION: CT</b> |  |

| Trial Tool and CTEV Contact Info  |   |
|---|---|
| <b>Clinical Trials Connection Tool</b><br><b>Match to a Clinical Trial in 60 Seconds</b>  |  |
| <b>Breakthrough T1D Greater New England Clinical Trial Education Volunteers</b><br><b>AmandaJGilchrist@gmail.com and Kristin.Neff@gmail.com</b> |   |